Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PDX1 associated lncRNA, upregulator of transcription (PLUT) is a human long non-coding RNA (lncRNA) gene, also known as PLUTO or HI-LNC71, that is enriched in pancreatic islet β-cells, with tissue-specific expression highly correlated with the nearby essential transcription factor gene PDX1[1][2][3][5][6][7][8]. PLUT directly regulates the transcription of PDX1, including influencing the local 3D chromatin structure at the PDX1 locus, which is critical for normal β-cell development and function[2][4][8]. Aberrant expression of PLUT is linked to β-cell dysfunction and islets from type 2 diabetes patients display decreased PLUT and PDX1 expression[2][4]. While modulation of PLUT impacts gene expression and β-cell function in vitro, it is not a traditional therapeutic target such as a protein receptor, enzyme, or transporter, and no specific drugs are known to interact with PLUT directly[2][7]. PLUT is studied for its regulatory and disease associations, particularly in diabetes, but is not currently used as a biomarker or therapeutic target in clinical practice[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PDX1 associated lncRNA, upregulator of transcription (PLUT).